Ladenburg Thalmann Initiates Coverage On Onconova Therapeutics with Buy Rating, Announces Price Target of $7
Ladenburg Thalmann analyst Ahu Demir initiates coverage on Onconova Therapeutics (NASDAQ:ONTX) with a Buy rating and announces Price Target of $7.
Onconova Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Onconova Therapeutics (NASDAQ:ONTX) reported Q2 sales of $57.00 thousand. Earnings fell to a loss of $4.64 million, resulting in a 13.35% decrease from last quarter.
Earnings Scheduled For November 11, 2021
Companies Reporting Before The Bell
• NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million.
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 4)
Onconova Therapeutics’s Return On Capital Employed Overview
Onconova Therapeutics (NASDAQ:ONTX) brought in sales totaling $57.00 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 13.35%, resulting in a loss of $4.64 million.
Onconova Therapeutics Announces Closing Of $21M Public Offering; Shares Move Higher
Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the
48 Biggest Movers From Friday
Gainers
ZIVO Bioscience, Inc. (NASDAQ: ZIVO) shares climbed 58% to close at $5.45 on Friday.